02.11.2023 07:00:32 - dpa-AFX: EQS-News: DKSH Technology Strengthens Its Business in Australia and New Zealand With the Acquisition of Bio-Strategy (english)

DKSH Technology Strengthens Its Business in Australia and New Zealand With
the Acquisition of Bio-Strategy

waiting on 1763077,news,alipes2

   DKSH Management Ltd. / Key word(s): Takeover
   DKSH Technology Strengthens Its Business in Australia and New
   Zealand With the Acquisition of Bio-Strategy
   02.11.2023 / 07:00 CET/CEST
     ____________________________________________________________


Media release

DKSH has signed an agreement to acquire Bio-Strategy Limited
('Bio-Strategy'), the largest independent distributor of scientific
instruments in Australia and New Zealand. With this acquisition, DKSH grows
its Scientific Instrumentation business in line with Business Unit
Technology's strategy to build resilience and deliver profitable growth.

Zurich, Switzerland, November 2, 2023 - DKSH has announced today that it
signed an agreement for the acquisition of Bio-Strategy, the largest
independent distributor of scientific instruments in Australia and New
Zealand, focusing primarily on life sciences, medical & healthcare and
environment & agriculture segments.

Established 2003 and based in Melbourne, Bio-Strategy generates net sales of
more than CHF 40 million1 at good profitability. With a team of over 100
people, the company serves renowned blue chip clients and distributes
products and services to around 1,200 customers. DKSH acquires 100% of the
business and its management team and employees will join DKSH's Business
Unit Technology.

Hanno Elbraechter, Head Business Unit Technology at DKSH, commented: 'I am
delighted with the acquisition of Bio-Strategy as an important addition to
DKSH. The specific industry and application knowledge of the company will
help us to solidify our position in two of Asia Pacific's key markets. While
complementing both DKSH Technology's product portfolio and regional
presence, the acquired expertise will enable us to create added value for
our clients and customers.'

John Chesterfield, CEO of Bio-Strategy, said: 'We are pleased about the
combination with DKSH, one of Asia's leading technology distribution
players, marking the next big step in our 20-year journey. In addition to a
wider regional reach and an enlarged product and service portfolio, our
clients, customers, employees, and business partners will benefit from
various synergies. We are excited about our shared future, to leverage our
common expertise and to continue successfully serving our stakeholders.'

The closing of the transaction is expected during the fourth quarter of 2023
and is subject to certain conditions.

1 Exchange rate 1 Swiss Franc / 1.88 NZD

For further information, please contact:

DKSH Holding Ltd.

Till Leisner

Head, Group Investor & Media Relations, Sustainability

Phone +41 44 386 7315

till.leisner@dksh.com

Melanie GrĂ¼ter

Manager Group Media Relations

Phone +41 44 386 7211

melanie.grueter@dksh.com

____________________________________________________________

   End of Media Release
     ____________________________________________________________


   Language:    English
   Company:     DKSH Management Ltd.
                Wiesenstrasse 8
                8008 Zurich
                Switzerland
   Phone:       044 386 72 72
   E-mail:      media@dksh.com
   Internet:    www.dksh.com
   ISIN:        CH0126673539
   Valor:       12667353
   Listed:      SIX Swiss Exchange
   EQS News ID: 1763077



   End of News EQS News Service
     ____________________________________________________________


1763077 02.11.2023 CET/CEST

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH